Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
7MW4911 in Advanced Gastrointestinal Cancers
NCT07216560Phase 2Recruiting
- Sponsor
- Mabwell
- Start
- Jan 2026
- Primary completion
- Jul 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of 7MW4911 in gastrointestinal cancer, sponsored by Mabwell. Started Jan 2026; status: recruiting.
02
Drugs
7MW4911
03
Conditions
gastrointestinal cancer
Beyond the preview
Go deeper on NCT07216560.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07216560.